Universal Biospecimen Collection Protocol for Extra Material From Clinical Pulmonary Procedures

May 18, 2026 updated by: M.D. Anderson Cancer Center

The goal of this study is to develop a biospecimen collection protocol for unused biospecimens from pulmonary procedures in order to facilitate research across many different areas of pulmonary medicine and mitigate the pulmonary morbidity experienced by patients with cancer.

Study Overview

Status

Recruiting

Conditions

Pulmonary

Detailed Description

Primary objectives:

To assemble a tissue/blood bank biorepository for laboratory translational research by collecting extra samples of bronchoalveolar lavage, pleural fluid, blood or other residual tissue obtained during normally scheduled clinical procedures for the evaluation of pulmonary toxicity

To collect basic data on patient data and suspected pulmonary toxicity to cross-reference eligible biospecimens

Study Type

Observational

Enrollment (Estimated)

12000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Ajay Sheshadri, MD
Phone Number: (713) 563-1987
Email: asheshadri@mdanderson.org

Study Locations

United States
- Texas
  - Houston, Texas, United States, 77030
    - Recruiting
    - The University of Texas M. D. Anderson Cancer Center
    - Principal Investigator:
      
      Ajay Sheshadri, MD
    - Contact:
      
      Ajay Sheshadri, MD
      
      Phone Number: 713-563-1987
      
      Email: asheshadri@mdanderson.org

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Adult
Older Adult

Accepts Healthy Volunteers

Sampling Method

Non-Probability Sample

Study Population

All patients scheduled for pulmonary procedures in the Cardiopulmonary Center are eligible to be approached for consent and enrollment into this observational biospecimen collection protocol.

Description

Inclusion Criteria:

All patients over the age of 18, who are seen in the Cardiopulmonary Center and are undergoing pulmonary procedures

Exclusion Criteria:

Pregnant women and prisoners

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and Adverse Events (AEs) Time Frame: Through study completion; an average of 1 year	Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0	Through study completion; an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.D. Anderson Cancer Center

Investigators

Principal Investigator: Ajay Sheshadri, MD, M.D. Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

MD Anderson Cancer Center Website

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 8, 2025

Primary Completion (Estimated)

December 1, 2030

Study Completion (Estimated)

December 1, 2032

Study Registration Dates

First Submitted

October 17, 2025

First Submitted That Met QC Criteria